Bookbuilding IPO | ₹[.] Cr | Listing at BSE, NSE |
Hindustan Laboratories Ltd. has filed a Draft Red Herring Prospectus (DRHP) with SEBI on January 3, 2026 to raise funds through Initial Public Offer (IPO).
Hindustan Laboratories Ltd. IPO is a Book Build Issue of 1.41 crore equity shares consisting of a fresh issue of upto 0.50 crore equity shares and an offer for sale (OFS) of upto 0.91 crore equity shares.
The equity shares are proposed to be listed on NSE and BSE. Choice Capital Advisors Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Hindustan Laboratories IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 1,41,00,000 shares (agg. up to ₹[.] Cr) |
| Fresh Issue | 50,00,000 shares (agg. up to ₹[.] Cr) |
| Offer for Sale | 91,00,000 shares of ₹10 (agg. up to ₹[.] Cr) |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Sat, Jan 3, 2026 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII Shares Offered | Not less than 15% of the Offer |
Incorporated in 2017, Hindustan Laboratories Limited is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework.
The company's roducts are supplied mainly through procurement contracts for central government healthcare projects under the Ministry of Health and Family Welfare via Government of India agencies, as well as through state government agencies and bodies.
Hindustan Laboratories Limited supplied products across India to 27 states and Union Territories during the six months ended September 30, 2025, and to 27 states and Union Territories during Fiscal 2025. The company served 343 customers during the six months ended September 30, 2025, and 445, 474, and 439 customers in Fiscal 2025, Fiscal 2024, and Fiscal 2023, respectively.
The product portfolio covers a wide range of therapeutic segments addressing both acute and chronic healthcare requirements. These include anti-allergic, anti-diabetic, anti-infective, anti-malarial, antiparasitic, blood-related, cardiac, gastrointestinal, keratolytic, pain and analgesic, respiratory therapies, nutritional and mineral supplements, and vitamin supplements.
The company has formulation capabilities across multiple dosage forms, including tablets, capsules, powders, oral liquids, topical solutions, creams, ointments, combination blister packs, and topical powders. The product portfolio increased from 661 products as of March 31, 2023 to 871 products as of March 31, 2025, and further expanded to 948 products as of September 30, 2025.
The manufacturing facility (Unit 1) is located at Palghar, Maharashtra, approximately 100 km from Mumbai along National Highway 8, with connectivity by road, rail, and air. The facility is certified under ISO 9001:2015 for quality management systems.
An additional manufacturing unit (Unit 2) is located at the Palghar facility and is intended to support capacity expansion. Unit 2 is currently under commissioning, and commercial production has not yet commenced.
As of September 30, 2025, the workforce consisted of 284 employees and 332 contract laborers.
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 242.95 | 225.49 | 176.35 | 145.40 |
| Total Income | 115.78 | 227.37 | 194.33 | 179.48 |
| Profit After Tax | 18.24 | 41.27 | 34.14 | 22.25 |
| EBITDA | 25.46 | 53.88 | 44.09 | 30.69 |
| NET Worth | 197.01 | 178.74 | 137.34 | 103.15 |
| Total Borrowing | 3.85 | 6.79 | 5.11 | 1.50 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding the working capital requirements. | 72.50 |
| 2 | General corporate purposes. |
| KPI | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROCE | 12.86% | 33.13% |
| RoNW | 9.71% | 26.11% |
| PAT Margin | 16.19% | 18.78% |
| EBITDA Margin | 22.60% | 24.52% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 8.28 | |
| Promoter Holding | 99.99% |
Lead Manager Reports
Hindustan Laboratories IPO is a main-board IPO of 1,41,00,000 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Hindustan Laboratories IPO open and close dates are not available as of now.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Hindustan Laboratories IPO using UPI as a payment gateway. Zerodha customers can apply in Hindustan Laboratories IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Hindustan Laboratories IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Hindustan Laboratories IPO dates are not announced. Please check back again after some time.
Hindustan Laboratories IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Hindustan Laboratories IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Hindustan Laboratories IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Hindustan Laboratories IPO allotment status.
The Hindustan Laboratories IPO listing date is not yet announced. The tentative date of listing is .
